Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04830137 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 20, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 2025 to May 2026 Completion date: Dec 2026 to May 2027v22 Show 1 more changeShow less
    • Completion date: Dec 2026 to May 2027
  2. Site details revised at 3 of 16 sitesv21
  3. Site details revised at 4 of 16 sitesv20
  4. Enrollment target: 266 to 248 Site details revised at 2 of 16 sitesv19 Show 1 more changeShow less
    • Site details revised at 2 of 16 sites
  5. Trial status: Active, Not Recruiting to Recruiting Enrollment target: 160 to 266 · Primary completion date: Dec 2024 to Dec 2025 · Completion date: Dec 2025 to Dec 2026 · 4 morev18 Show 7 more changesShow less
    • Enrollment target: 160 to 266
    • Primary completion date: Dec 2024 to Dec 2025
    • Completion date: Dec 2025 to Dec 2026
    • Eligibility criteria shortened, about 55 words
    • Study description expanded, about 27 words
    • Study sites revised (16)
    • Study arms: 6 to 11

    See this version in full on ClinicalTrials.gov ↗

Show 16 earlier versionsHide 16 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Site details revised at 16 of 16 sitesv17 Show 1 more changeShow less
    • Site details revised at 16 of 16 sites
  2. Primary completion date: Oct 2023 to Dec 2024 Completion date: Nov 2023 to Dec 2025 · Secondary endpoints: details revised at 6 of 6 entriesv16 Show 2 more changesShow less
    • Completion date: Nov 2023 to Dec 2025
    • Secondary endpoints: details revised at 6 of 6 entries
  3. Primary endpoints revised (4) Study sites: 15 to 16 · Eligibility criteria expanded, about 22 words · Study description shortened, about 5 wordsv15 Show 3 more changesShow less
    • Study sites: 15 to 16
    • Eligibility criteria expanded, about 22 words
    • Study description shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 14 to 15v14
  5. Study sites: 13 to 14v13
  6. Study sites: 12 to 13v12
  7. Enrollment target: 130 to 160 Eligibility criteria expanded, about 111 words · Study description expanded, about 20 wordsv11 Show 2 more changesShow less
    • Eligibility criteria expanded, about 111 words
    • Study description expanded, about 20 words

    See this version in full on ClinicalTrials.gov ↗

  8. Re-verified, no change to tracked fieldsv10
  9. Study sites: 11 to 12v9
  10. Eligibility criteria shortened, about 89 words Study description expanded, about 1 wordv8 Show 1 more changeShow less
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  11. Study sites: 10 to 11v7
  12. Study sites: 8 to 10v6
  13. Study sites: 7 to 8v5
  14. Study sites: 6 to 7v4
  15. Study sites: 4 to 6 Start date changed from estimate of Apr 2021 to May 5, 2021 · Eligibility criteria shortened, about 7 words · Secondary endpoints: 5 to 6 · 1 morev3 Show 4 more changesShow less
    • Start date changed from estimate of Apr 2021 to May 5, 2021
    • Eligibility criteria shortened, about 7 words
    • Secondary endpoints: 5 to 6
    • Study description expanded, about 16 words

    See this version in full on ClinicalTrials.gov ↗

  16. Study sites: 3 to 4v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Nurix Therapeutics, Inc.
7 trials monitored
See 1 trial at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
DLBCL
650 trials monitored
See 38 trials at risk
and 3 more diseases
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Trial Details
NCT Number NCT04830137
Lead Sponsor Nurix Therapeutics, Inc.
Conditions Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
Enrollment 248 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov